Global Non-Insulin Therapies for Diabetes Market Research Report 2021
Exclusive deal : 20% Instant discount on Direct purchases! Don't wait—claim your discount today!
Research Predicts that Non-Insulin Therapies for Diabetes Market was valued USD xxxx unit in 2020 and is expected to reach USD xxxx Unit by the year 2025, growing at a CAGR of xx% globally.
Global Non-Insulin Therapies for Diabetes Market Overview:
Global Non-Insulin Therapies for Diabetes Market Report 2020 comes with the extensive industry analysis of development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2020-2025.This research study of Non-Insulin Therapies for Diabetes involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Impact of COVID-19 on Non-Insulin Therapies for Diabetes Market
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost every country around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affected the Non-Insulin Therapies for Diabetes market in 2020.
Global Non-Insulin Therapies for Diabetes Market Segmentation
By Type, Non-Insulin Therapies for Diabetes market has been segmented into:
Alpha-glucosidase Inhibitors
Amylin Agonists
Biguanides
Dipeptidyl Peptidase-4 (DPP4) Inhibitors
Glinides / Meglitinides
GLP-1 Analogs / GLP-1 Agonists
Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
Sulfonylureas
Thiazolidinediones
Others
By Application, Non-Insulin Therapies for Diabetes market has been segmented into:
Hospital Pharmacy
Retail Pharmacies
Online Pharmacy
Others
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain etc.)
Asia-Pacific (China, India, Japan, Southeast Asia etc.)
South America (Brazil, Argentina etc.)
Middle East & Africa (Saudi Arabia, South Africa etc.)
Top Key Players Covered in Non-Insulin Therapies for Diabetes market are:
GSK
Eli Lilly
Sumitomo Dainippon Pharma
Intarcia Therapeutics
Servier
Jiangsu Hansoh Pharmaceutical
Novo Nordisk
Emisphere
Uni-Bio Science Group
Takeda
3SBio
Merck
Dong-A Pharmaceutical
Luye Pharma Group
Eurofarma
Geropharm
Alkem Labs
SatRx
Pfizer
Jiangsu Hengrui Medicine
1. Market Overview of Non-Insulin Therapies for Diabetes
1.1 Non-Insulin Therapies for Diabetes Market Overview
1.1.1 Non-Insulin Therapies for Diabetes Product Scope
1.1.2 Market Status and Outlook
1.2 Non-Insulin Therapies for Diabetes Market Size by Regions: 2015 VS 2021 VS 2026
1.3 Non-Insulin Therapies for Diabetes Historic Market Size by Regions (2015-2020)
1.4 Non-Insulin Therapies for Diabetes Forecasted Market Size by Regions (2021-2026)
1.5 Covid-19 Impact on Key Regions, Keyword Market Size YoY Growth (2015-2026)
1.5.1 North America
1.5.2 East Asia
1.5.3 Europe
1.5.4 South Asia
1.5.5 Southeast Asia
1.5.6 Middle East
1.5.7 Africa
1.5.8 Oceania
1.5.9 South America
1.5.10 Rest of the World
1.6 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
1.6.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.6.2 Covid-19 Impact: Commodity Prices Indices
1.6.3 Covid-19 Impact: Global Major Government Policy
2. Covid-19 Impact Non-Insulin Therapies for Diabetes Sales Market by Type (2015-2026)
2.1 Global Non-Insulin Therapies for Diabetes Historic Market Size by Type (2015-2020)
2.2 Global Non-Insulin Therapies for Diabetes Forecasted Market Size by Type (2021-2026)
2.3 Alpha-glucosidase Inhibitors
2.4 Amylin Agonists
2.5 Biguanides
2.6 Dipeptidyl Peptidase-4 (DPP4) Inhibitors
2.7 Glinides / Meglitinides
2.8 GLP-1 Analogs / GLP-1 Agonists
2.9 Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
2.10 Sulfonylureas
2.11 Thiazolidinediones
2.12 Others
3. Covid-19 Impact Non-Insulin Therapies for Diabetes Sales Market by Application (2015-2026)
3.1 Global Non-Insulin Therapies for Diabetes Historic Market Size by Application (2015-2020)
3.2 Global Non-Insulin Therapies for Diabetes Forecasted Market Size by Application (2021-2026)
3.3 Hospital Pharmacy
3.4 Retail Pharmacies
3.5 Online Pharmacy
3.6 Others
4. Covid-19 Impact Market Competition by Manufacturers
4.1 Global Non-Insulin Therapies for Diabetes Production Capacity Market Share by Manufacturers (2015-2020)
4.2 Global Non-Insulin Therapies for Diabetes Revenue Market Share by Manufacturers (2015-2020)
4.3 Global Non-Insulin Therapies for Diabetes Average Price by Manufacturers (2015-2020)
5. Company Profiles and Key Figures in Non-Insulin Therapies for Diabetes Business
5.1 GSK
5.1.1 GSK Company Profile
5.1.2 GSK Non-Insulin Therapies for Diabetes Product Specification
5.1.3 GSK Non-Insulin Therapies for Diabetes Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.2 Eli Lilly
5.2.1 Eli Lilly Company Profile
5.2.2 Eli Lilly Non-Insulin Therapies for Diabetes Product Specification
5.2.3 Eli Lilly Non-Insulin Therapies for Diabetes Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.3 Sumitomo Dainippon Pharma
5.3.1 Sumitomo Dainippon Pharma Company Profile
5.3.2 Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Product Specification
5.3.3 Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.4 Intarcia Therapeutics
5.4.1 Intarcia Therapeutics Company Profile
5.4.2 Intarcia Therapeutics Non-Insulin Therapies for Diabetes Product Specification
5.4.3 Intarcia Therapeutics Non-Insulin Therapies for Diabetes Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.5 Servier
5.5.1 Servier Company Profile
5.5.2 Servier Non-Insulin Therapies for Diabetes Product Specification
5.5.3 Servier Non-Insulin Therapies for Diabetes Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.6 Jiangsu Hansoh Pharmaceutical
5.6.1 Jiangsu Hansoh Pharmaceutical Company Profile
5.6.2 Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Product Specification
5.6.3 Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.7 Novo Nordisk
5.7.1 Novo Nordisk Company Profile
5.7.2 Novo Nordisk Non-Insulin Therapies for Diabetes Product Specification
5.7.3 Novo Nordisk Non-Insulin Therapies for Diabetes Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.8 Emisphere
5.8.1 Emisphere Company Profile
5.8.2 Emisphere Non-Insulin Therapies for Diabetes Product Specification
5.8.3 Emisphere Non-Insulin Therapies for Diabetes Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.9 Uni-Bio Science Group
5.9.1 Uni-Bio Science Group Company Profile
5.9.2 Uni-Bio Science Group Non-Insulin Therapies for Diabetes Product Specification
5.9.3 Uni-Bio Science Group Non-Insulin Therapies for Diabetes Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.10 Takeda
5.10.1 Takeda Company Profile
5.10.2 Takeda Non-Insulin Therapies for Diabetes Product Specification
5.10.3 Takeda Non-Insulin Therapies for Diabetes Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.11 3SBio
5.11.1 3SBio Company Profile
5.11.2 3SBio Non-Insulin Therapies for Diabetes Product Specification
5.11.3 3SBio Non-Insulin Therapies for Diabetes Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.12 Merck
5.12.1 Merck Company Profile
5.12.2 Merck Non-Insulin Therapies for Diabetes Product Specification
5.12.3 Merck Non-Insulin Therapies for Diabetes Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.13 Dong-A Pharmaceutical
5.13.1 Dong-A Pharmaceutical Company Profile
5.13.2 Dong-A Pharmaceutical Non-Insulin Therapies for Diabetes Product Specification
5.13.3 Dong-A Pharmaceutical Non-Insulin Therapies for Diabetes Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.14 Luye Pharma Group
5.14.1 Luye Pharma Group Company Profile
5.14.2 Luye Pharma Group Non-Insulin Therapies for Diabetes Product Specification
5.14.3 Luye Pharma Group Non-Insulin Therapies for Diabetes Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.15 Eurofarma
5.15.1 Eurofarma Company Profile
5.15.2 Eurofarma Non-Insulin Therapies for Diabetes Product Specification
5.15.3 Eurofarma Non-Insulin Therapies for Diabetes Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.16 Geropharm
5.16.1 Geropharm Company Profile
5.16.2 Geropharm Non-Insulin Therapies for Diabetes Product Specification
5.16.3 Geropharm Non-Insulin Therapies for Diabetes Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.17 Alkem Labs
5.17.1 Alkem Labs Company Profile
5.17.2 Alkem Labs Non-Insulin Therapies for Diabetes Product Specification
5.17.3 Alkem Labs Non-Insulin Therapies for Diabetes Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.18 SatRx
5.18.1 SatRx Company Profile
5.18.2 SatRx Non-Insulin Therapies for Diabetes Product Specification
5.18.3 SatRx Non-Insulin Therapies for Diabetes Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.19 Pfizer
5.19.1 Pfizer Company Profile
5.19.2 Pfizer Non-Insulin Therapies for Diabetes Product Specification
5.19.3 Pfizer Non-Insulin Therapies for Diabetes Production Capacity, Revenue, Price and Gross Margin (2015-2020)
5.20 Jiangsu Hengrui Medicine
5.20.1 Jiangsu Hengrui Medicine Company Profile
5.20.2 Jiangsu Hengrui Medicine Non-Insulin Therapies for Diabetes Product Specification
5.20.3 Jiangsu Hengrui Medicine Non-Insulin Therapies for Diabetes Production Capacity, Revenue, Price and Gross Margin (2015-2020)
6. North America
6.1 North America Non-Insulin Therapies for Diabetes Market Size (2015-2026)
6.2 North America Non-Insulin Therapies for Diabetes Key Players in North America (2015-2020)
6.3 North America Non-Insulin Therapies for Diabetes Market Size by Type (2015-2020)
6.4 North America Non-Insulin Therapies for Diabetes Market Size by Application (2015-2020)
7. East Asia
7.1 East Asia Non-Insulin Therapies for Diabetes Market Size (2015-2026)
7.2 East Asia Non-Insulin Therapies for Diabetes Key Players in North America (2015-2020)
7.3 East Asia Non-Insulin Therapies for Diabetes Market Size by Type (2015-2020)
7.4 East Asia Non-Insulin Therapies for Diabetes Market Size by Application (2015-2020)
8. Europe
8.1 Europe Non-Insulin Therapies for Diabetes Market Size (2015-2026)
8.2 Europe Non-Insulin Therapies for Diabetes Key Players in North America (2015-2020)
8.3 Europe Non-Insulin Therapies for Diabetes Market Size by Type (2015-2020)
8.4 Europe Non-Insulin Therapies for Diabetes Market Size by Application (2015-2020)
9. South Asia
9.1 South Asia Non-Insulin Therapies for Diabetes Market Size (2015-2026)
9.2 South Asia Non-Insulin Therapies for Diabetes Key Players in North America (2015-2020)
9.3 South Asia Non-Insulin Therapies for Diabetes Market Size by Type (2015-2020)
9.4 South Asia Non-Insulin Therapies for Diabetes Market Size by Application (2015-2020)
10. Southeast Asia
10.1 Southeast Asia Non-Insulin Therapies for Diabetes Market Size (2015-2026)
10.2 Southeast Asia Non-Insulin Therapies for Diabetes Key Players in North America (2015-2020)
10.3 Southeast Asia Non-Insulin Therapies for Diabetes Market Size by Type (2015-2020)
10.4 Southeast Asia Non-Insulin Therapies for Diabetes Market Size by Application (2015-2020)
11. Middle East
11.1 Middle East Non-Insulin Therapies for Diabetes Market Size (2015-2026)
11.2 Middle East Non-Insulin Therapies for Diabetes Key Players in North America (2015-2020)
11.3 Middle East Non-Insulin Therapies for Diabetes Market Size by Type (2015-2020)
11.4 Middle East Non-Insulin Therapies for Diabetes Market Size by Application (2015-2020)
12. Africa
12.1 Africa Non-Insulin Therapies for Diabetes Market Size (2015-2026)
12.2 Africa Non-Insulin Therapies for Diabetes Key Players in North America (2015-2020)
12.3 Africa Non-Insulin Therapies for Diabetes Market Size by Type (2015-2020)
12.4 Africa Non-Insulin Therapies for Diabetes Market Size by Application (2015-2020)
13. Oceania
13.1 Oceania Non-Insulin Therapies for Diabetes Market Size (2015-2026)
13.2 Oceania Non-Insulin Therapies for Diabetes Key Players in North America (2015-2020)
13.3 Oceania Non-Insulin Therapies for Diabetes Market Size by Type (2015-2020)
13.4 Oceania Non-Insulin Therapies for Diabetes Market Size by Application (2015-2020)
14. South America
14.1 South America Non-Insulin Therapies for Diabetes Market Size (2015-2026)
14.2 South America Non-Insulin Therapies for Diabetes Key Players in North America (2015-2020)
14.3 South America Non-Insulin Therapies for Diabetes Market Size by Type (2015-2020)
14.4 South America Non-Insulin Therapies for Diabetes Market Size by Application (2015-2020)
15. Rest of the World
15.1 Rest of the World Non-Insulin Therapies for Diabetes Market Size (2015-2026)
15.2 Rest of the World Non-Insulin Therapies for Diabetes Key Players in North America (2015-2020)
15.3 Rest of the World Non-Insulin Therapies for Diabetes Market Size by Type (2015-2020)
15.4 Rest of the World Non-Insulin Therapies for Diabetes Market Size by Application (2015-2020)
16 Non-Insulin Therapies for Diabetes Market Dynamics
16.1 Covid-19 Impact Market Top Trends
16.2 Covid-19 Impact Market Drivers
16.3 Covid-19 Impact Market Challenges
16.4 Porter’s Five Forces Analysis
18 Regulatory Information
17 Analyst's Viewpoints/Conclusions
18 Appendix
18.1 Research Methodology
18.1.1 Methodology/Research Approach
18.1.2 Data Source
18.2 Disclaimer
Research Methodology:
Non Insulin Therapies for Diabetes Market Size Estimation
To estimate market size and trends, we use a combination of top-down and bottom-up methods. This allows us to evaluate the market from various perspectives—by company, region, product type, and end users.
Our estimates are based on actual sales data, excluding any discounts. Segment breakdowns and market shares are calculated using weighted averages based on usage rates and average prices. Regional insights are determined by how widely a product or service is adopted in each area.
Key companies are identified through secondary sources like industry reports and company filings. We then verify revenue estimates and other key data points through primary research, including interviews with industry experts, company executives, and decision-makers.
We take into account all relevant factors that could influence the market and validate our findings with real-world input. Our final insights combine both qualitative and quantitative data to provide a well-rounded view. Please note, these estimates do not account for unexpected changes such as inflation, economic downturns, or policy shifts.
Data Source
Secondary Sources
This study draws on a wide range of secondary sources, including press releases, annual reports, non-profit organizations, industry associations, government agencies, and customs data. We also referred to reputable databases and directories such as Bloomberg, Wind Info, Hoovers, Factiva, Trading Economics, Statista, and others. Additional references include investor presentations, company filings (e.g., SEC), economic data, and documents from regulatory and industry bodies.
These sources were used to gather technical and market-focused insights, identify key players, analyze market segmentation and classification, and track major trends and developments across industries.
| Market Size |
|
|
| Market Position of Top Company |
|
|
| Qualitative Analysis |
|
|
Primary Sources
As part of our primary research, we interviewed a variety of stakeholders from both the supply and demand sides to gather valuable qualitative and quantitative insights.
On the supply side, we spoke with product manufacturers, competitors, industry experts, research institutions, distributors, traders, and raw material suppliers. On the demand side, we engaged with business leaders, marketing and sales heads, technology and innovation directors, supply chain executives, and end users across key organizations.
These conversations helped us better understand market segmentation, pricing, applications, leading players, supply chains, demand trends, industry outlook, and key market dynamics—including risks, opportunities, barriers, and strategic developments.
Key Data Information from Primary Sources
| Primary Sources | Parameters | Key Data |
| Market Segments(by Application, by Type) |
|
|
| Total Market |
|
|